Clin Ophthalmol. 2012;6:1681-7. doi: 10.2147/OPTH.S35338. Epub 2012 Oct 16.

Microperimetric evaluation of chronic central serous chorioretinopathy after half-dose photodynamic therapy.

Clinical ophthalmology (Auckland, N.Z.)

Kyoko Fujita, Kei Shinoda, Celso Soiti Matsumoto, Yutaka Imamura, Etsuko Tanaka, Yoshihiro Mizutani, Atsushi Mizota, Mitsuko Yuzawa

PMID: 23097612 PMCID: PMC3476484 DOI: 10.2147/OPTH.S35338

Abstract

BACKGROUND: The purpose of this study was to determine baseline clinical factors to correlate the outcome of half-dose verteporfin photodynamic therapy (PDT) in eyes with chronic central serous chorioretinopathy (CSC).

METHODS: In this prospective, non-comparative, interventional case series, 14 eyes of 14 patients with chronic CSC who received half-dose verteporfin PDT were examined. The best-corrected visual acuity (BCVA), macular sensitivity in the central 4, 8, and 12 degrees, and fixation stability were evaluated at baseline and at months 1, 3, 6, and 12 after half-dose verteporfin PDT. Macular sensitivity and fixation stability were determined by MP-1 microperimetry.

RESULTS: Mean retinal sensitivity in the central 4 and 8 degrees was significantly better at 1, 3, 6, and 12 months after half-dose verteporfin PDT than at baseline. BCVA was significantly better after half-dose verteporfin PDT but only after 3 months. Fixation was relatively unstable in three eyes at baseline, but became stable at 12 months. BCVA at 12 months was significantly correlated with pre-PDT fixation stability (r = 0.7120, P = 0.0038).

CONCLUSION: Half-dose verteporfin PDT results in a significant increase in mean central retinal sensitivity for at least 12 months. Our findings indicate that microperimetry is a useful method for evaluating the functional benefits of half-dose verteporfin PDT in eyes with chronic CSC.

Keywords: chronic central serous chorioretinopathy; fixation point; microperimetry; photodynamic therapy; retinal sensitivity

References

1. Retina. 2003 Dec;23(6):752-63 - PubMed
2. Retina. 2011 Apr;31(4):772-8 - PubMed
3. Retina. 2000;20(6):633-7 - PubMed
4. Eye (Lond). 2008 Feb;22(2):204-8 - PubMed
5. Ophthalmology. 2008 Oct;115(10):1756-65 - PubMed
6. Eye (Lond). 2011 Feb;25(2):149-53 - PubMed
7. Am J Ophthalmol. 2011 Feb;151(2):303-9.e1 - PubMed
8. Am J Ophthalmol. 2008 Jul;146(1):77-84 - PubMed
9. Acta Ophthalmol. 2011 May;89(3):e293-4 - PubMed
10. Am J Ophthalmol. 2011 Jun;151(6):953-960.e2 - PubMed
11. Eur J Ophthalmol. 2009 Jan-Feb;19(1):154-8 - PubMed
12. Graefes Arch Clin Exp Ophthalmol. 2002 Sep;240(9):748-57 - PubMed
13. Br J Ophthalmol. 2003 Dec;87(12):1453-8 - PubMed
14. Arch Ophthalmol. 1984 Sep;102(9):1299-302 - PubMed
15. Arch Ophthalmol. 1999 Feb;117(2):184-8 - PubMed
16. Am J Ophthalmol. 2003 Dec;136(6):1067-78 - PubMed
17. Nippon Ganka Gakkai Zasshi. 1970 Aug;74(8):957-64 - PubMed
18. Arch Ophthalmol. 2002 Jun;120(6):835-44 - PubMed
19. Am J Ophthalmol. 2010 Feb;149(2):307-315.e2 - PubMed
20. Br J Ophthalmol. 2011 Apr;95(4):514-7 - PubMed
21. Retina. 2010 Sep;30(8):1254-61 - PubMed
22. Ophthalmology. 2005 May;112(5):848-54 - PubMed
23. Retina. 2003 Jun;23(3):288-98 - PubMed
24. Jpn J Ophthalmol. 2010 Nov;54(6):578-83 - PubMed
25. Am J Ophthalmol. 1988 Nov 15;106(5):546-50 - PubMed
26. Eye (Lond). 1987;1 ( Pt 1):120-5 - PubMed

Publication Types

• Journal Article